Jaguar Health, Inc. 8-K

What Happened Jaguar Health announced on June 17, 2026 that it amended royalty agreements with Uptown Capital and Streeterville Capital. The Uptown amendment sets the monthly royalty payment, beginning October 1, 2026, as the greater of $750,000 or the actual royalty amount due; the Streeterville amendment similarly sets a $750,000-or-actual monthly minimum and delays the start of monthly payments from July 1, 2026 to October 1, 2026. On the same date the company amended a 2021 secured promissory note with Streeterville to extend its maturity from July 1, 2026 to October 1, 2026. Separately, in three private exchange transactions in June 2026 the company issued a total of 110,249 shares of common stock to Streeterville in exchange for outstanding Series Q preferred shares, which were cancelled.

Key Details

• Royalty amendments (Uptown & Streeterville) set a monthly minimum payment of $750,000 starting October 1, 2026 (payment will be the greater of $750,000 or the actual royalty due).
• Streeterville amendment also delays the initiation of monthly royalty payments from July 1, 2026 to October 1, 2026.
• The 2021 secured promissory note’s maturity was extended from July 1, 2026 to October 1, 2026 by amendment dated June 17, 2026.
• Jaguar issued 34,798 shares (June 9), 36,796 shares (June 17) and 38,655 shares (June 18) — total 110,249 common shares — to Streeterville in exchange for Series Q preferred shares that were then cancelled; the combined issuance exceeded 5% of outstanding common stock as of the company’s May 20, 2026 10‑Q.

Why It Matters These amendments increase Jaguar Health’s guaranteed potential cash obligation beginning October 1, 2026 by establishing a $750,000 monthly royalty floor (unless actual royalties are higher), which could meaningfully affect cash flow and liquidity planning. The note extension pushes repayment obligations to October 1, 2026, giving short-term relief on the loan maturity date. The exchange transactions converted preferred stock into common shares and resulted in issuance of more than 5% of the company’s common stock as previously reported, which dilutes existing shareholders and eliminated the exchanged preferred shares’ separate claims. Investors should note the timing (October 1, 2026) and the fixed monthly minimum when assessing near-term cash needs and dilution impact.